STANDARD BIOTOOLS INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $85.3M | $91.0M | $106.3M | $97.9M | $130.6M |
| Cost of revenue | $42.8M | $46.1M | $55.9M | $60.9M | — |
| Gross profit | $42.5M | $44.9M | $50.5M | $37.1M | — |
| Selling, general & administrative | $109.9M | $103.1M | $87.5M | $102.3M | $98.9M |
| Research and development | $26.0M | $28.8M | $25.9M | $37.4M | $37.9M |
| Operating expenses | $152.8M | $172.4M | $127.0M | $153.3M | $198.0M |
| Operating income | -$110.2M | -$127.5M | -$76.6M | -$116.2M | -$67.5M |
| Interest expense | — | — | $4.6M | $4.3M | $3.8M |
| Pretax income | -$96.7M | -$90.4M | -$74.2M | -$192.9M | -$63.7M |
| Income tax expense | -$37.9M | $542,000 | $452,000 | -$2.8M | -$4.4M |
| Net income | -$74.9M | -$138.9M | -$74.7M | -$190.1M | -$59.2M |
| Balance Sheet | |||||
| Cash and equivalents | $120.9M | $166.7M | $51.7M | $81.3M | $28.5M |
| Current assets | $454.3M | $375.9M | $158.2M | $208.8M | $72.1M |
| Total assets | $567.8M | $612.3M | $323.1M | $390.3M | $275.2M |
| Current liabilities | $108.3M | $65.9M | $109.3M | $43.4M | $49.6M |
| Total liabilities | $143.5M | $140.6M | $159.9M | $160.5M | $180.6M |
| Total debt | — | — | $7.9M | — | — |
| Stockholders' equity | $424.3M | $471.7M | -$148.1M | -$81.5M | $94.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$74.3M | -$143.5M | -$43.3M | -$89.4M | -$44.1M |
| Depreciation and amortization | $9.3M | $12.5M | $12.7M | $12.5M | $3.2M |
| Stock-based compensation | $29.6M | $31.7M | $13.1M | $14.9M | $16.1M |
| Capital expenditure | $8.3M | $8.4M | $2.8M | $3.8M | $13.3M |
| Free cash flow | -$82.6M | -$151.8M | -$46.1M | -$93.2M | -$57.3M |
| Share repurchases | $0 | $40.5M | $5.4M | $563,000 | $0 |
| Impairments | $0 | $0 | $0 | $3.5M | $0 |
Shares outstanding 390.1M · Free float 28.3%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.